it would seem that GLP-1 use for weight loss would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this. The pharmacy benefit manager Prime ...
In July, the company changed tactics on its weight lossdrug, cutting the daily dose from two to one. The company is currently engaged in clinical trials on danuglipron, with results expected to ...
GLP-1weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly ...
Some results have been hidden because they may be inaccessible to you